Stockscreener 앱 받기
4.25
6.59%
-0.30
시간 외 거래:
4.17
-0.08
-1.88%
전일 마감가:
$4.55
열려 있는:
$4.58
하루 거래량:
435.51K
Relative Volume:
1.14
시가총액:
$102.68M
수익:
$68.38M
순이익/손실:
$-20.17M
주가수익비율:
-4.8082
EPS:
-0.8839
순현금흐름:
$-14.13M
1주 성능:
+1.43%
1개월 성능:
+16.76%
6개월 성능:
-33.70%
1년 성능:
-45.02%
1일 변동 폭
$4.16
$4.74
1주일 범위
$4.11
$4.85
52주 변동 폭
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
명칭
Exagen Inc
전화
(760) 560-1501
주소
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
4.25 | 110.41M | 68.38M | -20.17M | -14.13M | -0.8839 |
TMO
Thermo Fisher Scientific Inc
|
461.69 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.76 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
546.09 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
124.33 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
357.00 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-11 | 개시 | B. Riley Securities | Buy |
| 2025-07-30 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-07-23 | 개시 | Craig Hallum | Buy |
| 2022-08-05 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-04-15 | 개시 | Canaccord Genuity | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-06-02 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-10-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-10-14 | 개시 | Cowen | Outperform |
| 2019-10-14 | 개시 | William Blair | Outperform |
모두보기
Exagen Inc 주식(XGN)의 최신 뉴스
Exagen Inc. (XGN) Q1 2026 Earnings: Adjusted Loss Narrows, Stock Gains in AftermathSegment Revenue Breakdown - newsline.com
Exagen Shareholders Approve Directors, Auditor and Pay Package - The Globe and Mail
Exagen | 8-K: Current report - Moomoo
Exagen (NASDAQ: XGN) shareholders approve directors, auditor and say-on-pay - Stock Titan
Exagen Company Profile & Introduction - Moomoo
XGN Q1 2026 Earnings: EPS Beats Estimates Despite Stock DeclineRevenue Surprise History - newsline.com
Exagen Inc. Q1 2026 Earnings: EPS Surprise Lifts but Revenue Disclosure Gap Weighs on SharesMargin Compression Risk - newsline.com
Exagen Inc. (XGN) Plunges 9.4% – Key Support Levels in Focus After Sharp SelloffIV Spike - newsline.com
Exagen study shows lupus test identifies 25% more patients By Investing.com - Investing.com South Africa
Exagen study shows lupus test identifies 25% more patients - Investing.com
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus - GlobeNewswire
Lupus test used on 1M patients finds cases routine lab work misses - Stock Titan
Exagen Inc. (XGN) Q1 2026 Earnings: EPS Beats Estimates by 15.15%, Revenue Details Withheld, Stock DeclinesBook Value Growth - The Legal Advocate
Record revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing losses - MSN
How much upside is left in Exagen (XGN)? Wall Street analysts think 73.05% - MSN
Exagen Inc. (XGN) reports Q1 loss, beats revenue estimates - MSN
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05% - Yahoo Finance
Parian Ultreia reports 5.3% stake in Exagen (NASDAQ: XGN) - Stock Titan
Exagen Inc. Q1 2026 Earnings: EPS Beat Surprises, but Revenue Details AbsentEstimate Accuracy - The Legal Advocate
XGN Q1 2026 Earnings: EPS Beat Highlights Cost Discipline Amid Revenue UncertaintyEarnings Weakness Phase - Newser
Exagen Inc. (XGN) Holds Steady Near Support Amid Low VolatilityLiquidity Sweep - The Legal Advocate
Exagen Inc. (XGN) Inches Lower as Shares Test Key Support Near $4.05Institutional Volume - The Legal Advocate
William Blair Maintains Exagen(XGN.US) With Buy Rating - Moomoo
Exagen Inc. Common Stock (XGN) Stock Price Today & Analysis - Gotrade
Exagen Inc. (XGN) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseRevenue Per Share - Newser
Earnings call transcript: Exagen Inc. beats Q1 2026 expectations, stock surges - Investing.com Nigeria
Exagen Inc stock (US30063K1051): 13G filing shows 9.9% stake - AD HOC NEWS
Exagen Earnings Call Highlights Growth Amid Headwinds - The Globe and Mail
EXAGEN (XGN) holder Jorey Chernett reports 2.41M shares, 9.9% - Stock Titan
Exagen (XGN) Rallies +8.02% as Bulls Target $3.96 2026-05-19Professional Trade Ideas - Newser
Exagen (XGN) Reports Strong Q1 2026 — Revenue $N/A, EPS BeatsEarnings Deceleration Risk - newsline.com
Exagen reaffirms $70M-$73M 2026 revenue guidance as it targets $600-$650 ASP over time - MSN
Why Exagen (XGN) Just Dropped -4.55% — What to Watch 2026-05-15TPO Profile - Newser
Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Exagen Targets $73 Million Revenue for 2026 as Test Volumes Surge - HarianBasis.co
Exagen Inc. (NASDAQ:XGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Exagen (XGN) Receives a Buy from BTIG - The Globe and Mail
TradingKey - TradingKey
Exagen Achieves Record Q1 Revenue Driven by AVISE CTD Adoption - HarianBasis.co
Exagen Inc (XGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Exagen Inc 주식 (XGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ABALLI JOHN | President and CEO |
Feb 24 '26 |
Sale |
3.61 |
11,430 |
41,262 |
702,997 |
| Black Jeffrey G. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.61 |
1,584 |
5,718 |
267,442 |
| ABALLI JOHN | President and CEO |
Oct 16 '25 |
Sale |
11.82 |
31,787 |
375,598 |
714,427 |
| Black Jeffrey G. | Chief Financial Officer |
Sep 02 '25 |
Sale |
9.79 |
20,466 |
200,362 |
269,026 |
1.63%
2.88%
자본화:
|
볼륨(24시간):